[Dialysis amyloidosis syndrome in patients aged over 55 years and undergoing a hemodialysis program]

The clinical-and-biochemical signs of the dialysis amyloidosis syndrome were studied in two groups of patients with chronic renal insufficiency (CRI), who have been undergoing a multi-year renal-substitutive therapy (program-type hemodialysis). The first group comprised 77 adult patients (aged 18-40), the second group comprised 49 "elderly" patients (aged 55-73). Apart from the standard analyses, the dynamics of beta 2-microglobulin (beta 2-M) was studied in the blood of patients. Specific features in the development of the syndrome of dialysis amyloidosis were described; they correlated with the level of beta 2-M, with a duration of program-type hemodialysis, with the elderly age of patients, with variants of renal pathologies, and with an concomitant diabetes mellitus.